“Adolescents diagnosed with multiple sclerosis (MS) have limited treatment options and few opportunities to participate in clinical research and potentially access new therapies, which is why I am very pleased that the Clinical Research Unit’s (CRU) first-ever pediatric trial was launched in record time thanks to CATALIS’ FAST TRACK evaluation service. The NEOS trial will compare the efficacy and safety of three standard adult treatments to determine which is best tolerated by, and most effective for, these young patients with MS.”
